Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
01 2023
Historique:
revised: 08 09 2022
received: 13 06 2022
accepted: 27 09 2022
pubmed: 6 10 2022
medline: 1 2 2023
entrez: 5 10 2022
Statut: ppublish

Résumé

Acute heart failure can be a life-threatening medical condition. Delaying administration of intravenous furosemide (time-to-diuretics) has been postulated to increase mortality, but prior reports have been inconclusive. We aimed to evaluate the association between time-to-diuretics and mortality in the international REPORT-HF registry. We assessed the association of time-to-diuretics within the first 24 h with in-hospital and 30-day post-discharge mortality in 15 078 patients from seven world regions in the REPORT-HF registry. We further tested for effect modification by baseline mortality risk (ADHERE risk score), left ventricular ejection fraction (LVEF) and region. The median time-to-diuretics was 67 (25th-75th percentiles 17-190) min. Women, patients with more signs and symptoms of heart failure, and patients from Eastern Europe or Southeast Asia had shorter time-to-diuretics. There was no significant association between time-to-diuretics and in-hospital mortality (p > 0.1). The 30-day mortality risk increased linearly with longer time-to-diuretics (administered between hospital arrival and 8 h post-hospital arrival) (p = 0.016). This increase was more significant in patients with a higher ADHERE risk score (p In REPORT-HF, longer time-to-diuretics was not associated with higher in-hospital mortality. However, we did found an association with increased 30-day mortality, particularly in high-risk patients, and irrespective of LVEF or geographic region. ClinicalTrials.gov Identifier NCT02595814.

Identifiants

pubmed: 36196060
doi: 10.1002/ejhf.2708
pmc: PMC10099670
doi:

Substances chimiques

Diuretics 0
Furosemide 7LXU5N7ZO5

Banques de données

ClinicalTrials.gov
['NCT02595814']

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-51

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Eur J Heart Fail. 2019 Oct;21(10):1187-1196
pubmed: 31419004
Eur Heart J. 2013 May;34(19):1404-13
pubmed: 23095984
JAMA Cardiol. 2020 Apr 1;5(4):401-410
pubmed: 31913404
Biometrics. 2001 Mar;57(1):120-5
pubmed: 11252586
Eur J Heart Fail. 2015 May;17(5):527-33
pubmed: 25754836
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur J Heart Fail. 2014 Dec;16(12):1283-91
pubmed: 25452165
Am Heart J. 2013 Aug;166(2):349-56
pubmed: 23895819
Eur J Heart Fail. 2022 Jan;24(1):4-131
pubmed: 35083827
Eur Heart J. 2021 Nov 14;42(43):4442-4451
pubmed: 34184057
Int J Cardiol. 2018 Oct 15;269:207-212
pubmed: 30041982
J Am Coll Cardiol. 2008 Aug 12;52(7):534-40
pubmed: 18687247
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
JAMA. 2005 Feb 2;293(5):572-80
pubmed: 15687312
JACC Heart Fail. 2018 Apr;6(4):286-294
pubmed: 29598933
Int J Cardiol. 2019 Jun 15;285:40-46
pubmed: 30905515
Circ Heart Fail. 2021 Apr;14(4):e007901
pubmed: 33866828
J Am Coll Cardiol. 2017 Jun 27;69(25):3042-3051
pubmed: 28641794
Lancet Glob Health. 2020 Mar;8(3):e411-e422
pubmed: 32087174
BMJ Open. 2014 Dec 30;4(12):e005988
pubmed: 25550294
Am J Cardiol. 2021 May 15;147:70-79
pubmed: 33617811
Eur J Heart Fail. 2015 Jun;17(6):544-58
pubmed: 25999021
JACC Heart Fail. 2018 Apr;6(4):295-297
pubmed: 29598934
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
J Am Heart Assoc. 2019 Sep 17;8(18):e012282
pubmed: 31495302

Auteurs

Wouter Ouwerkerk (W)

National Heart Centre Singapore, Singapore.
Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, The Netherlands.

Jasper Tromp (J)

Duke-National University of Singapore, Singapore.
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.

John G F Cleland (JGF)

Robertson Centre for Biostatistics and Clinical Trials, Institute of Health & Well-Being, University of Glasgow and National Heart & Lung Institute, Imperial College, London, UK.

Christiane E Angermann (CE)

University and University Hospital Würzburg, Comprehensive Heart Failure Center, Würzburg, Germany.

Ulf Dahlstrom (U)

Department of Cardiology and Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden.

Georg Ertl (G)

University and University Hospital Würzburg, Comprehensive Heart Failure Center, Würzburg, Germany.

Mahmoud Hassanein (M)

Department of Cardiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Sergio V Perrone (SV)

El Cruce Hospital by Florencio Varela, Lezica Cardiovascular Institute, Sanctuary of the Trinidad Miter, Buenos Aires, Argentina.

Mathieu Ghadanfar (M)

M-Ghadanfar Consulting (Life Sciences), Basel, Switzerland.

Anja Schweizer (A)

Novartis Pharma AG, Basel, Switzerland.

Achim Obergfell (A)

Novartis Pharma AG, Basel, Switzerland.

Kenneth Dickstein (K)

University of Bergen, Stavanger University Hospital, Stavanger, Norway.

Gerasimos Filippatos (G)

School of Medicine, Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Sean P Collins (SP)

Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Carolyn S P Lam (CSP)

National Heart Centre Singapore, Singapore.
Duke-National University of Singapore, Singapore.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH